Many cancer cells rely heavily on glucose (the Warburg effect) and cannot efficiently use ketones. A strict ketogenic diet may starve these tumors while nourishing healthy cells. In one case, it led to a 70% reduction in cancer markers in six weeks, far exceeding chemotherapy's expected 30%.

Contrary to trends in wellness, a full-body MRI doesn't catch cancer early. A mass visible on an MRI already contains billions of cells and may have spread. Furthermore, it often leads to a rabbit hole of invasive tests for benign abnormalities, causing unnecessary harm.

The medical community is slow to adopt advanced preventative tools like genomic sequencing. Change will not come from the top down. Instead, educated and savvy patients demanding these tests from their doctors will be the primary drivers of the necessary revolution in personalized healthcare.

CZI's New York Biohub is treating the immune system as a programmable platform. They are engineering cells to navigate the body, detect disease markers like heart plaques, record this information in their DNA, and then be read externally, creating a living diagnostic tool.

The NIH's cancellation of mRNA research is a profound strategic error. The technology's key advantage is speed, which is critical not only for future pandemics but also for personalized cancer treatments. These therapies must be developed for individual patients quickly, making mRNA the most promising platform.

AI finds the most efficient correlation in data, even if it's logically flawed. One system learned to associate rulers in medical images with cancer, not the lesion itself, because doctors often measure suspicious spots. This highlights the profound risk of deploying opaque AI systems in critical fields.

A 7-year study of healthy individuals over 85 found minimal genetic differences from their less healthy counterparts. The key to their extreme healthspan appears to be a robust immune system, which is significantly shaped by lifestyle choices, challenging the common narrative about being born with "good genes."

Chronic illnesses like cancer, heart disease, and Alzheimer's typically develop over two decades before symptoms appear. This long "runway" is a massive, underutilized opportunity to identify high-risk individuals and intervene, yet medicine typically focuses on treatment only after a disease is established.

The future of biotech moves beyond single drugs. It lies in integrated systems where the 'platform is the product.' This model combines diagnostics, AI, and manufacturing to deliver personalized therapies like cancer vaccines. It breaks the traditional drug development paradigm by creating a generative, pan-indication capability rather than a single molecule.